Regeneron Pharmaceuticals (NSDQ:REGN) touted one-year results from a Phase III trial of its Eylea aflibercept injection in people with moderately severe to severe non-proliferative diabetic retinopathy.
The primary endpoint of the two-year Panorama trial is the proportion of patients who experience a two-step or greater improvement in the ‘diabetic retinopathy severity scale.’
Get the full story at our sister site, Drug Delivery Business News.
The post Regeneron touts one-year diabetic retinopathy data for Eylea appeared first on MassDevice.